Tevogen Bio 使用 ExacTcell™ 技术扩展肿瘤学产品线，用于癌症治疗和 COVID-19。 Tevogen Bio expands oncology pipeline using ExacTcell™ tech for cancer treatments and COVID-19.
临床阶段生物技术公司Tevogen Bio正在扩大其产品线,以利用其ExacTcellTM技术改善瘤治疗和癌症患者的持续护理. Tevogen Bio, a clinical-stage biotech firm, is expanding its pipeline to enhance oncology treatments and continuous care for cancer patients using their ExacTcell™ technology. 它们旨在发展现成的、基因未改变的治疗癌症和传染病的T型细胞疗法,包括COVID-19。 They aim to develop off-the-shelf, genetically unmodified T cell therapies for cancers and infectious diseases, including COVID-19. 该公司未来的增长取决于能否获得额外资金、应对法律挑战以及面临市场竞争。 The company's future growth depends on securing additional funding, navigating legal challenges, and facing market competition.